Skip to Main Content

Paper Details

Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition.
J Invest Dermatol
23
2020
-, Glutathione, MAPK Kinase, MAPK kinase, MEK, MEKi, MEKi-resistant cells, Melanomas, NRAS, NRAS mutations, NRAS-, NRAS-Mutant Melanoma, NRAS-mutant melanoma, PD0325901, PHGDH, Resistant NRAS-Mutant Melanoma, Tumors, extracellular signal-regulated kinase 1/2, human, human NRAS-mutant melanoma xenografts, resistant cells, serine, trametinib
Author NameAffiliation
Michael A DaviesThe University of Texas, MD Anderson Cancer Center
Michael A DaviesThe University of Texas, MD Anderson Cancer Center
Katherine L NathansonPerelman School of Medicine, University of Pennsylvania
Phil F ChengUniversity of Zurich Hospital, University of Zurich
Phil F ChengUniversity of Zurich Hospital, University of Zurich
Mitchell P LevesqueUniversity of Zurich Hospital, University of Zurich
Mitchell P LevesqueUniversity of Zurich Hospital, University of Zurich
Reinhard DummerUniversity of Zurich Hospital, University of Zurich
Reinhard DummerUniversity of Zurich Hospital, University of Zurich
Andrew E AplinSidney Kimmel Cancer Center, Thomas Jefferson University, USA Sidney Kimmel Cancer Center
  • 1 - 10

Datasets

Release 1.2